NIPRO JMI Pharma

What NIPRO JMI Pharma does

NIPRO JMI Pharma Ltd. (NJP) is a private joint venture pharmaceutical manufacturer established in 2012 in Dhaka, Bangladesh, formed as a 51:49 partnership between NIPRO Corporation (Japan) and JMI Group (Bangladesh), with US$10.5 million of NIPRO's US$23 million three-project investment allocated to the pharmaceutical entity. The company manufactures and markets finished pharmaceutical products in compliance with WHO cGMP guidelines at a dedicated facility in Cumilla, with segregated buildings for penicillin, cephalosporin and general formulations, a quality control laboratory, a modern R&D department, HVAC systems and an effluent treatment plant. Its product portfolio spans diabetes (SGLT2 and DPP4 inhibitors), cardiovascular, antibiotics (including cephalosporins and carbapenems), respiratory, allergy, gastroenterology, neurology, nutritional supplements, and specialty liver-disease medications.

NJP operates a sales-led go-to-market model, deploying a 1,800+ member sales force across Bangladesh to reach healthcare professionals, pharmacies, and distributors, while leveraging NIPRO Corporation's global network of 74 sales companies for international exports. The company employs between 1,001 and 5,000 staff across its Dhaka headquarters and Cumilla manufacturing site. Revenue mechanics are based on one-time product sales of branded prescription generics; no pricing or licensing details are publicly disclosed. The strategic positioning combines low-cost Bangladesh manufacturing with Japanese quality standards and parent-company distribution reach, targeting both the growing Bangladesh domestic market (estimated 15-20% annual growth) and selective international markets via NIPRO's channel.

Name

NIPRO JMI Pharma

Legal name

NIPRO JMI Pharma Ltd.

Website

https://niprojmipharma.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

NIPRO JMI Pharma Ltd. is a Bangladesh-based joint venture (NIPRO Corporation Japan 51% / JMI Group 49%) that manufactures and markets WHO cGMP-compliant pharmaceutical products across diabetes, cardiovascular, antibiotics, and specialty therapeutics, serving Bangladesh healthcare professionals and international markets via NIPRO's global sales network.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Pharmaceutical manufacturing
• Prescription medications
• Generic drug production
• CGMP pharmaceutical formulations
• Bangladesh pharmaceutical exports

Headquarters

HQ city

Dhaka

HQ country

Bangladesh

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and marketing of pharmaceutical products including hormonal, injectable, ophthalmic products, and general formulations for domestic Bangladesh market and global exports

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

NIPRO JMI Pharma manufactures and markets pharmaceutical finished dosage products in compliance with cGMP guidelines recommended by the WHO. Its product portfolio spans diabetes medications (SGLT2 inhibitors and DPP-4 inhibitors), antibiotics (cephalosporins, carbapenems), cardiovascular drugs, anticoagulants, respiratory, allergy, gastroenterology, neurology, nutritional supplements, and specialty products for liver disease, distributed domestically through its own sales force and internationally via NIPRO Corporation's 74-country sales network.

Product overview

NIPRO JMI Pharma Ltd. is a Japan-Bangladesh joint venture pharmaceutical company manufacturing and marketing pharmaceutical products. The company operates a cGMP-compliant manufacturing facility producing a portfolio of prescription medications across multiple therapeutic categories. The product portfolio includes diabetes medications (Empa, EmpaMet, Lijenta 5, Lijenta-M, Emjenta - various SGLT2 inhibitors and DPP4 inhibitors), cardiovascular products (Losarva, Enoject anticoagulant), antibiotics (Nixon, MEROXIN, Xinarox CV), respiratory medications (Montiva, Doxiva), allergy treatments (Bilfast), gastroenterology products (RABLET), neurological medications (Pandura), nutritional supplements (Calgi-D, V3N), and specialty products for liver diseases (Fibrocon, Fibritor). The company also offers extended-release formulations like Flexivan ER.

Differentiator

Problem solved

Functional benefit

Products and services

• Empa Empagliflozin oral medication for the treatment of type 2 diabetes, prescribed by physicians and dispensed through pharmacies.
• EmpaMet Fixed-dose combination of Empagliflozin and Metformin Hydrochloride for management of type 2 diabetes.
• Lijenta 5 Linagliptin 5 mg oral medication for the treatment of type 2 diabetes.
• Lijenta-M Fixed-dose combination of Linagliptin and Metformin Hydrochloride for management of type 2 diabetes.
• Emjenta Fixed-dose combination of Empagliflozin INN and Linagliptin INN for the treatment of type 2 diabetes.
• Doxiva Doxophylline oral formulation for the management of respiratory conditions such as asthma and COPD.
• Bilfast Bilastine oral antihistamine used for the treatment of allergic conditions.
• Calgi-D Calcium (Algae source) 500 mg and Vitamin D3 200 IU oral supplement used to support bone and nutritional health.
• RABLET Rabeprazole Sodium proton pump inhibitor used for gastric acid-related disorders such as GERD and peptic ulcers.
• Xinarox CV Cefuroxime and Clavulanic Acid combination antibiotic for the treatment of bacterial infections.
• Pandura Clonazepam oral formulation used in the management of neurological and psychiatric conditions such as seizures and anxiety.
• Losarva Losartan Potassium oral angiotensin receptor blocker for the treatment of cardiovascular conditions such as hypertension.
• V3N Oral combination of Vitamin B1, Vitamin B6 and Vitamin B12 used as a nutritional supplement, typically for nerve health.
• Montiva Montelukast oral leukotriene receptor antagonist used for the management of respiratory conditions such as asthma and allergic rhinitis.
• Flexivan ER Aceclofenac extended-release oral NSAID for the management of pain and inflammation.
• Nixon

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• NIPRO CorporationcoreStrategic or Co-development Partner · 13 March 2012Japanese multinational pharmaceutical and medical device company that invested US$ 23 million to form the joint venture. NIPRO Corporation holds 51% stake and brings global manufacturing expertise, 23 production units worldwide, and 74 international sales companies for global marketing of products manufactured in Bangladesh.
• JMI GroupcoreStrategic or Co-development Partner · 13 March 2012Bangladeshi pharmaceutical group and existing distributor of NIPRO Corporation products in Bangladesh. Holds 49% stake in the joint venture company and contributes local market expertise and distribution network.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Aristopharma Limited: Established Bangladeshi generic manufacturer with broad therapeutic coverage including cardiology, diabetes, and antibiotics. Directly comparable in scale, product mix, and Bangladesh market channel competition.
• Healthcare Pharmaceuticals: Mid-sized Bangladeshi pharmaceutical manufacturer with a diversified branded-generic portfolio. Comparable in therapeutic breadth, manufacturing scale, and Bangladesh domestic channel competition.
• Renata Limited: Bangladesh-based pharmaceutical company with strong presence in animal health and human generics, including endocrine and cardiometabolic products. Comparable in therapeutic categories and domestic Bangladesh market positioning.
• Incepta Pharmaceuticals: One of Bangladesh's top generic manufacturers with a wide therapeutic portfolio including diabetes, cardiology, and specialty injectables. Closely comparable in product mix, scale, and Bangladesh-centric manufacturing footprint.
• Beximco Pharmaceuticals: Leading Bangladeshi exporter of branded generics with a portfolio spanning chronic-disease and acute-care therapies. Directly comparable to NIPRO JMI Pharma in domestic manufacturing scale, generic portfolio breadth, and international export ambitions.
• ACI Limited (Pharma Division): Bangladeshi conglomerate with a sizable pharmaceutical manufacturing arm producing branded generics across multiple therapeutic classes. Competes in the same domestic market and channels as NIPRO JMI Pharma.
• Drug International Limited: Bangladesh-based pharmaceutical company producing generics across multiple therapeutic categories. Comparable mid-tier scale and overlapping product mix in the domestic Bangladeshi market.
• Square Pharmaceuticals: Bangladesh's largest pharmaceutical manufacturer with a broad branded-generic portfolio across diabetes, cardiovascular, antibiotics, and other therapeutic areas. Competes head-to-head with NIPRO JMI Pharma in the same HCP channel and Bangladeshi domestic market.
• Eskayef Pharmaceuticals: Bangladeshi manufacturer focused on branded generics and specialty formulations including hormones, sterile, and biotech products. Closely comparable to NIPRO JMI Pharma's stated pivot toward higher-complexity therapies.

Broad incumbents

• NIPRO Corporation (Pharma Division): Japanese parent corporation with global pharmaceutical and medical device operations including 23 production units worldwide. Comparable as the controlling parent providing technology, manufacturing standards, and the 74-country distribution network that anchors NIPRO JMI Pharma's export channel.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/niprojmi2012
• Facebookfacebook.com/NIPROJMIPharma
• LinkedInlinkedin.com/company/nipro-jmi-pharma-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NIPRO JMI Pharma